68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor. (2nd February 2018)

• Record Type: Journal Article
• Authors: Shell, Jasmine; Keutgen, Xavier M; Millo, Corina; Nilubol, Naris; Patel, Dhaval; Sadowski, Samira; Boufraqech, Myriem; Yang, Lily; Merkel, Roxanne; Atallah, Christine; Herscovitch, Peter; Kebebew, Electron
• Is Part Of: International journal of endocrine oncology. Volume 5:Number 1(2018)
• Publication Date: 2018-02-02
• Subjects: 68-Gallium DOTATATE -- biochemistry -- carcinoid -- neuroendocrine tumor -- symptoms; Endocrine glands -- Cancer -- Periodicals; 616.9944005
• DOI: 10.2217/ije-2017-0005
• Languages: English
• ISSNs: 2045-0869

Abstract

Aim: The study's aim was to determine the utility of 68-Gallium DOTATATE positron emission tomography (PET)-CT scanning in patients with carcinoid-like symptoms and negative anatomical imaging.Methods: Retrospective analysis of 22 of 196 patients with carcinoid-like symptoms and no evidence of primary neuroendocrine tumor (NET) based on anatomical imaging and endoscopy who underwent 68-Gallium DOTATATE PET-CT as part of a prospective clinical trial.Results: Of the biochemically positive patients (n = 11), 18% (n = 2) had additional evidence of NETs based on 68-Gallium DOTATATE PET-CT. Of the patients identified by 68-Gallium DOTATATE PET-CT, 50% (n = 1) had a treatment change and 100% showed symptom improvement. Of the biochemically negative patients (n = 11), 68-Gallium DOTATATE PET-CT identified NETs in 64% (n = 7). Change in management occurred in 71% patients, and 57% of patients showed symptom improvement.Conclusion: 68-Gallium DOTATATE PET-CT imaging is useful in detecting NETs in symptomatic patients with negative anatomical imaging and changes the treatments in these patients.